Answers are grounded in this paper and cite their sources.
CRP actively promotes a proatherosclerotic and proinflammatory phenotype. These effects are mediated, in part, via the production of ET-1 and IL-6 and are attenuated by mixed ET(A/B) receptor antagonism and IL-6 inhibition. Bosentan may be useful in decreasing CRP-mediated vascular disease.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: